Product information and disease descriptionProduct descriptionProduct informationDosing and administration
Administration
8 evidence topics · 8 sources
Administration: single MRI-guided convection-enhanced stereotactic delivery into the caudate and putamen
Number of infusions per hemisphere
Burr holes and micro-catheter placement under general anesthesia
Procedure duration stated in the eligibility criteria of the European study
Delivery method described in a review of neurosurgical therapies for Huntington's disease
“In clinical trials, a current Phase 1/2 study funded by UniQure Biopharma includes patients with early manifestations of HD (ages 25–65 years) and uses bilateral striatal injection of AAV5-mHTT using an MRI-guided convection-enhanced delivery method and sham surgery for the randomized control arm” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although technically possible, manual infusion does not offer the control and consistency of more advanced techniques” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“namely MRI-guided convection-based delivery using a pressure gradient generated by a pump.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Stereotactic neurosurgical techniques will be critical in optimizing therapeutic efficacy through safe, reproducible treatment delivery.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Convection-enhanced delivery: method and the role of real-time imaging
“CED, on the other hand, uses a pressure gradient generated by an automated pump to distribute high concentrations of macromolecules over significant volumes within the brain parenchyma by fluid convection, allowing for measurable, consistent and predictable infusion rates.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“One major challenge has been the lack of real-time visualisation of vector delivery, without which it is difficult to improve the distribution of vector during infusions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This new paradigm allows visualisation of the accuracy and adequacy of viral vector delivery within target structures, enabling intertrial modifications in surgical approaches, cannula design, vector volumes and dosing.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cannula design and backflow during intraparenchymal infusion
“Features of the design of the infusion cannula for CED can profoundly impact successful delivery of gene therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Combined with increased infusion flow rates, these modifications resulted in greatly improved target coverage when evaluated in NHPs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Administration of the approved intraputaminal gene therapy eladocagene exuparvovec: setting and infusion parameters
| Field | Quoted record |
|---|---|
| Total recommended dose | “1.8x1011 vg (0.32 mL)” |
| Volume (dose) per infusion | “0.08 mL (0.45x1011 vg)” |
| Location of infusions | “2 in anterior putamen, 2 in posterior putamen” |
| Infusion rate at each target point | “0.003 mL/min” |
| Dose duration for infusion at each target point | “27 minutes” |